Login / Signup

Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.

Adriano VendittiAlfonso PiciocchiAnna CandoniValentina ArenaRaffaele PalmieriCarla FilìAngelo Michele CarellaValeria CalafioreRoberto CairoliPaolo De FabritiisGabriella StortiPrassede SalutariFrancesco LanzaGiovanni MartinelliAntonio CurtiMario LuppiClaudia IngrossoMaria Paola MartelliAntonio CuneoFrancesco AlbanoAntonino MulèAgostino TafuriLaura CudilloAlessia TieghiNicola Stefano FracchiollaDebora CapelliSilvia Maria TrisoliniCaterina AlatiEdoardo La SalaLuca MaurilloMaria Ilaria Del PrincipeMaria Antonietta Irno ConsalvoMaria Domenica DivonaTiziana OttoneRaffaella CerrettiGiuseppe SconocchiaMaria Teresa Teresa VosoPaola FaziMarco VignettiFrancesco Buccisano
Published in: Blood advances (2024)
Keyphrases
  • acute myeloid leukemia
  • allogeneic hematopoietic stem cell transplantation
  • study protocol
  • phase iii
  • clinical trial
  • phase ii
  • middle aged
  • randomized controlled trial
  • acute lymphoblastic leukemia